[go: up one dir, main page]

AR108975A1 - Anticuerpos con baja inmunogenicidad y sus usos - Google Patents

Anticuerpos con baja inmunogenicidad y sus usos

Info

Publication number
AR108975A1
AR108975A1 ARP170101865A ARP170101865A AR108975A1 AR 108975 A1 AR108975 A1 AR 108975A1 AR P170101865 A ARP170101865 A AR P170101865A AR P170101865 A ARP170101865 A AR P170101865A AR 108975 A1 AR108975 A1 AR 108975A1
Authority
AR
Argentina
Prior art keywords
antibodies
low immunogenicity
immunogenicity
methods
binding fragments
Prior art date
Application number
ARP170101865A
Other languages
English (en)
Inventor
Hari Hariharan
Jeonghoon Sun
Bellos Hadjivassiliou
Lawrence Dearth
Jeffrey Johnson
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AR108975A1 publication Critical patent/AR108975A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Anticuerpos y fragmentos de fijación al antígeno de estos con baja inmunogenicidad o sin inmunogenicidad en seres humanos y, opcionalmente, con propiedades de fabricación deseadas. También composiciones que comprenden tales anticuerpos o fragmentos de fijación al antígeno, métodos para usar tales anticuerpos y métodos para fabricar tales anticuerpos.
ARP170101865A 2016-07-06 2017-07-05 Anticuerpos con baja inmunogenicidad y sus usos AR108975A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662359150P 2016-07-06 2016-07-06

Publications (1)

Publication Number Publication Date
AR108975A1 true AR108975A1 (es) 2018-10-17

Family

ID=60913146

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101865A AR108975A1 (es) 2016-07-06 2017-07-05 Anticuerpos con baja inmunogenicidad y sus usos

Country Status (19)

Country Link
US (1) US11427632B2 (es)
EP (1) EP3481862A4 (es)
JP (1) JP7120989B2 (es)
KR (1) KR20190035737A (es)
CN (1) CN109689684B (es)
AR (1) AR108975A1 (es)
AU (1) AU2017292752B2 (es)
BR (1) BR112019000166A2 (es)
CA (1) CA3029977A1 (es)
CL (1) CL2019000019A1 (es)
CO (1) CO2019001112A2 (es)
EA (1) EA201990218A1 (es)
EC (1) ECSP19008417A (es)
IL (1) IL264009A (es)
MX (1) MX2019000172A (es)
SG (1) SG11201811788SA (es)
TW (1) TW201811824A (es)
WO (1) WO2018009499A1 (es)
ZA (1) ZA201900070B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ761568A (en) 2017-08-02 2022-11-25 Phanes Therapeutics Inc Anti-cd47 antibodies and uses thereof
KR102115300B1 (ko) * 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
TW202045550A (zh) * 2019-04-05 2020-12-16 美商西建公司 腫瘤選擇性結合cd47之抗體之工程
CN114206912B (zh) 2019-06-07 2025-02-11 Alx肿瘤生物技术公司 用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂
KR20230083300A (ko) 2020-10-07 2023-06-09 셀진 코포레이션 림프계 악성 신생물 병태의 이중특이성 항체 치료
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340288C (en) 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
GB9026912D0 (en) 1990-12-11 1991-01-30 Wessex Instrumentation Limited Reaction detection equipment
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
EP2316487B1 (en) * 2003-04-11 2014-06-11 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
US20060228350A1 (en) 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
US7354854B2 (en) 2005-05-24 2008-04-08 Texas Instruments Incorporated Nickel silicide method and structure
CN101189265B (zh) 2005-06-01 2012-07-04 米克罗麦特股份公司 抗il2抗体
TW200815470A (en) 2006-03-30 2008-04-01 Novartis Ag Compositions and methods of use for antibodies of c-Met
EP2121756A4 (en) * 2006-12-20 2011-08-31 Mmrglobal Inc ANTIBODIES AND PROCESS FOR THEIR PREPARATION AND USE
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
KR101721187B1 (ko) 2009-12-23 2017-03-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역원성의 감소 방법
PL2536764T3 (pl) 2010-02-18 2018-12-31 Ose Immunotherapeutics Humanizowane przeciwciała anty-CD28
ES2743203T3 (es) 2012-02-06 2020-02-18 Inhibrx Inc Anticuerpos CD47 y métodos de uso de los mismos
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
JP6826367B2 (ja) 2012-08-31 2021-02-03 ストロ バイオファーマ インコーポレーテッド アジド基を含む修飾アミノ酸
MX2015010115A (es) 2013-02-06 2016-05-31 Inhibrx Llc Anticuerpos cd47 de no agotamiento de plaquetas y no agotamiento de globulos rojos y metodos de uso de los mismos.
WO2016073906A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
CN107406503B (zh) 2014-11-18 2021-07-16 詹森药业有限公司 Cd47抗体、方法和用途
AU2015374301B2 (en) * 2014-12-30 2021-02-11 Celgene Corporation Anti-CD47 antibodies and uses thereof
GB2558131B (en) * 2015-09-21 2021-05-19 Surface Oncology Inc Anti-CD47 antibodies and methods of use

Also Published As

Publication number Publication date
BR112019000166A2 (pt) 2019-10-01
MX2019000172A (es) 2019-09-26
CO2019001112A2 (es) 2019-02-19
AU2017292752A1 (en) 2019-01-24
JP2019524087A (ja) 2019-09-05
KR20190035737A (ko) 2019-04-03
CN109689684A (zh) 2019-04-26
US20190241654A1 (en) 2019-08-08
CL2019000019A1 (es) 2019-06-28
EA201990218A1 (ru) 2019-07-31
EP3481862A1 (en) 2019-05-15
ECSP19008417A (es) 2019-02-28
CA3029977A1 (en) 2018-01-11
CN109689684B (zh) 2022-09-23
US11427632B2 (en) 2022-08-30
AU2017292752B2 (en) 2023-07-27
SG11201811788SA (en) 2019-01-30
WO2018009499A1 (en) 2018-01-11
IL264009A (en) 2019-01-31
TW201811824A (zh) 2018-04-01
JP7120989B2 (ja) 2022-08-17
ZA201900070B (en) 2023-08-30
EP3481862A4 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
UY40829A (es) Anticuerpos anti-phf-tau y sus usos
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
AR108975A1 (es) Anticuerpos con baja inmunogenicidad y sus usos
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
ECSP18095014A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
CO2018003436A2 (es) Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
BR112019012343A2 (pt) anticorpos il-11ra
BR112019002579A2 (pt) anticorpos biespecíficos fab monovalentes, assimétricos e tandem
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
CR20170095A (es) Anticuerpos anti-cll-1 e inmunoconjugados referencias recíprocas con solicitudes relacionadas
CR20180529A (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada
MX378368B (es) Receptores de antigeno y usos de los mismos.
MX389103B (es) Anticuerpos contra ticagrelor y métodos de uso.
BR112018068671A2 (pt) anticorpos monoclonais neutralizantes para il-25 e usos dos mesmos
AR106132A1 (es) Variantes optimizadas de anticuerpos anti-vegf